Research output: Chapter in Book/Report/Conference proceeding › Chapter
| Original language | English |
|---|---|
| Title of host publication | Therapies for Retinal Degeneration |
| Subtitle of host publication | Targeting Common Processes |
| Publisher | Royal Society of Chemistry |
| Pages | 81-124 |
| Number of pages | 44 |
| Edition | 65 |
| DOIs | |
| Published | 1 Jan 2019 |
| Additional links |
| Name | RSC Drug Discovery Series |
|---|---|
| Number | 65 |
| Volume | 2019-January |
| ISSN (Print) | 2041-3203 |
| ISSN (Electronic) | 2041-3211 |
Since their discovery in Streptomyces bacteria over half a century ago, pyrrolobenzodiazepines (PBDs) have generated significant interest as potential chemotherapeutic agents due to their sequence-selective DNA alkylating capacity. The development of synthetic PBD compounds from their naturally derived bacterial counterparts has enhanced both the potency and safety profiles of PBDs. Interestingly, such modifications of traditional PBD cores have sometimes led to an expansion of the mechanism of action of these compounds from simple DNA alkylation. This review documents one such change in mechanism of action of the PBDs, which has been engineered through chemical modifications of traditional PBD structures: the inhibition of transcription factor activity.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454